Diagnostic Value of the Serum Platelet-Activating Factor Acetylhydrolase Activity in Inflammatory Bowel Disease

Oshimoto, Hirokazu; Okamura, Shinichi; Iida, Tomohiro; Ishikawa, Takeshi; Hosaka, Kohei; Mori, Masatomo

doi:10.1620/tjem.207.65

Cited by 7 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The administration of recombinant PAF-AH reduces disease severity in animal models of asthma and acute pancreatitis [6,8]. Furthermore, plasma PAF-AH activity is decreased in patients with Crohn's disease and rheumatoid arthritis [17,27]. Therefore, we suggest that PAF-AH also plays a role in the pathogenesis of SSc.…”

Section: Introductionmentioning

confidence: 85%

Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis

et al. 2011

View full text Add to dashboard Cite

Platelet-activating factor acetylhydrolase (PAF-AH) has been demonstrated to be one of anti-inflammatory and anti-apoptotic factors, suggesting the potential to be involved in the development of systemic sclerosis (SSc). The aim of this study is to determine serum PAF-AH levels and their clinical associations in patients with SSc. Serum PAF-AH levels were examined by enzyme-linked immunosorbent assay in 57 patients with SSc and 24 healthy individuals. Serum PAF-AH levels were significantly elevated in SSc patients (130.4 ± 69.5 ng/ml) compared with healthy individuals (81.6 ± 34.8 ng/ml; P < 0.001). Among SSc patients, there were no differences in serum PAF-AH levels between those with diffuse cutaneous SSc (135.5 ± 79.3 ng/ml; n = 29) and those with limited cutaneous SSc (125.1 ± 58.6 ng/ml; n = 28). Patients with SSc who had raised PAF-AH levels less often had digital ulcers and arthritis/arthralgias than those with normal PAF-AH levels. The results show that serum PAF-AH levels were increased in patients with SSc and associated with a lower frequency of pitting scars/digital ulcers and arthritis/arthralgias. PAF-AH could be a protective factor against the development of digital ulcers and arthritis/arthralgia in this disease and as such would be a useful serological marker for disease severity.

show abstract

Section: Introductionmentioning

confidence: 85%

Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Esto podría constatarse con la correlación directa entre la actividad de la enzima y el conteo de plaquetas que se observó en los pacientes del presente estudio. Sin embargo, en otras enfermedades, como la inflamatoria intestinal, se describe lo contrario (28).…”

Section: Forma Clínicaunclassified

“…Este mediador juega un papel importante en las reacciones alérgicas e inflamatorias (26), y actúa como una molécula de señalización intercelular y vascular en los procesos inflamatorios (27). Su función es estimular la agregación plaquetaria y leucocitaria, la contracción del músculo liso y la vasodilatación (28), así como el aumento de la permeabilidad vascular y, dependiendo de su regulación, puede conducir a diferentes estados de la enfermedad (27).…”

unclassified

“…El factor activador de plaquetas (FAP), en su forma biológicamente inactiva es mediado por la enzima acetilhidrolasa del factor activador de plaquetas (AH-FAP) (26,28,29 Acetilhidrolasa del factor activador de plaquetas, grupos étnicos y dengue phospho-lipase A2, lp-PLA2), degrada los productos de la oxidación de fosfatidilcolina producidos por las lipoproteínas de baja densidad y del estrés oxidativo; por lo tanto, se considera una enzima potencialmente antiinflamatoria y, dependiendo de su concentración y de la disponibilidad de sustratos potenciales, puede poseer una doble función proinflamatoria y antiinflamatoria (30).…”

unclassified

See 1 more Smart Citation

Actividad sérica de la acetilhidrolasa del factor activador de plaquetas en pacientes afrodescendientes y mestizos con dengue, Colombia

et al. 2011

View full text Add to dashboard Cite

599Acetilhidrolasa del factor activador de plaquetas, grupos étnicos y dengue ARTÍCULO ORIGINAL Actividad sérica de la acetilhidrolasa del factor activador de plaquetas en pacientes afrodescendientes y mestizos con dengue, Colombia Palabras clave: 1-alquil-2-acetil-glicerofosfocolina esterasa, dengue, grupos étnicos, Colombia. Serum platelet-activating factor acetylhydrolase activity in dengue patients of African or mestizo descendencyIntroduction: Severe dengue infection is characterized by enhanced vascular permeability produced by cytokines and biochemical mediators. One of these mediators is the platelet-activating factor. Degradation of platelet-activating factor is accomplished by its specific acetylhydrolase. Down or up regulation of this enzyme has been linked to several diseases. However, the role of this enzyme in dengue infection is unknown, a well as whether differential activity occurs by ethnic group. Objective: The activity of the platelet-activating factor-acetylhydrolase was compared in patients infected with dengue virus in two ethnic groups. Material and methods: A descriptive, prospective and longitudinal study was made in two states of Colombia (Antioquia and Chocó). Serum samples were taken from 43 mestizo patients and 33 patients of African descent, each taken during five consecutive days of the acute dengue phase. A second serum sample was taken during the convalescent phase. Results:The mestizo patients showed higher frequency of dengue hemorrhagic fever than the patients of African descent (23.3% vs. 12.1%, p=0.25). The serum activity of the platelet-activating factor acetylhydrolase was higher in African descendents than in mestizos (0. Contribución de los autores:Berta Nelly Restrepo: idea de la investigación, escritura del proyecto, análisis de la información y escritura del manuscrito. Margarita Arboleda: captación de pacientes en la región de Urabá y revisión del artículo. Ruth Ramírez: elaboración de la bases de datos y procesamiento de las muestras de laboratorio. Gonzalo Álvarez: análisis de la información y escritura del manuscrito. Biomédica 2011;31:599-607 600Restrepo BN, Arboleda M, Ramírez R, Álvarez GConclusion. An increased production of platelet-activating factor-acetylhydrolase occurs in the serum of dengue-infected African descendants. However, a study of the frequencies of polymorphisms for this enzyme will permit more conclusive support for these observations.

show abstract

“…Its expression is readily upregulated by inflammatory stimuli, suggesting a potential role in the early phases of response to vessel injury. Most studies have attributed an inflammatory role to Lp-PLA 2 and sPLA 2 [9, 10]. In addition, studies suggest that Lp-PLA 2 is positively associated with insulin resistance and predicts the incidence of T2DM [11].…”

Section: Introductionmentioning

confidence: 99%

Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetes

Lin

et al. 2016

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundChina has the highest absolute disease burden of diabetes worldwide. For diabetic patients, diabetes-related vascular complications are major causes of morbidity and mortality. The roles of lipoprotein-associated phospholipase A2 (Lp-PLA2) and secretory phospholipase A2 (sPLA2) as inflammatory markers have been recently evaluated in the pathogenesis of both diabetes and atherosclerosis. We aimed to determine the mechanism through which patients with newly diagnosed type 2 diabetes gain long-term vascular benefit from intensive insulin therapy by evaluating the change in Lp-PLA2 and sPLA2 levels after early intensive insulin treatment and its relevance with insulin resistance and pancreatic β-cell function.MethodsIn total, 90 patients with newly diagnosed type 2 diabetes mellitus were enrolled. All patients received continuous subcutaneous insulin infusion (CSII) for approximately 2 weeks. Intravenous glucose-tolerance test (IVGTT) and oral glucose-tolerance test (OGTT) were performed, and plasma concentrations of Lp-PLA2 and sPLA2 were measured before and after CSII.ResultsLevels of Lp-PLA2 and sPLA2 were significantly higher in diabetic patients with macroangiopathy than in those without (P < 0.05). After CSII, the sPLA2 level decreased significantly in all diabetic patients (P < 0.05), while the Lp-PLA2 level changed only in those with macroangiopathy (P < 0.05). The area under the curve of insulin in IVGTT and OGTT, the acute insulin response (AIR3–5), early phase of insulin secretion (ΔIns30/ΔG30), modified β-cell function index, and homeostatic model assessment for β-cell function (HOMA-β) increased after treatment even when adjusted for the influence of insulin resistance (IR; P < 0.001). The HOMA-IR was lower after treatment, and the three other indicators adopted to estimate insulin sensitivity (ISIced, IAI, and QUICKI) were higher after treatment (P < 0.05). Correlation analysis showed that the decrease in the Lp-PLA2 and sPLA2 levels was positively correlated with a reduction in HOMA-IR after CSII (P < 0.05). Additionally, multiple linear regression analysis showed that Lp-PLA2 and sPLA2 independently correlated with HOMA-IR (P < 0.05).ConclusionsLp-PLA2 and sPLA2 are closely related to insulin resistance and macroangiopathy in diabetic patients. Intensive insulin therapy might help improve IR and protect against diabetic macroangiopathy by influencing the Lp-PLA2 and sPLA2 levels.Trial registration ChiCTR-TRC-10001618 2010 September 16.

show abstract

Diagnostic Value of the Serum Platelet-Activating Factor Acetylhydrolase Activity in Inflammatory Bowel Disease

Cited by 7 publications

References 31 publications

Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis

Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis

Actividad sérica de la acetilhidrolasa del factor activador de plaquetas en pacientes afrodescendientes y mestizos con dengue, Colombia

Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetes

Contact Info

Product

Resources

About